Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Various guidelines recommend that patients with early rheumatoid arthritis (RA) try to achieve clinical remission within 6 months, and early therapeutic intervention is important to this end. This study aimed to investigate short-term treatment outcomes of patients with early-diagnosed RA in clinical practice and to examine predictive factors for achieving remission.
Methods: Of the 210 patients enrolled in the multicenter RA inception cohort, 172 patients who were followed up to 6 months after treatment initiation (baseline) were included. Logistic regression analysis was used to examine the impact of baseline characteristics on achievement of Boolean remission at 6 months.
Results: Participants (mean age, 62 years) initiated treatment after a mean of 19 days from RA diagnosis. At baseline and 3 and 6 months after treatment initiation, proportions of patients using methotrexate (MTX) were 87.8%, 89.0%, and 88.3%, respectively, and rates of Boolean remission were 1.8%, 27.8%, and 34.5%, respectively. Multivariate analysis revealed that physician global assessment (PhGA) (Odds ratio (OR): 0.84, 95% confidence interval (CI): 0.71-0.99) and glucocorticoid use (OR: 0.26, 95% CI: 0.10-0.65) at baseline were independent factors that predicted Boolean remission at 6 months.
Conclusion: After a diagnosis of RA, satisfactory therapeutic effects were achieved at 6 months after the initiation of treatment centered on MTX according to the treat to target strategy. PhGA and glucocorticoid use at treatment initiation are useful for predicting the achievement of treatment goals.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jos.2023.03.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Repeat stereotactic radiosurgery for treatment of brain metastases locally recurrent following initial radiosurgery.
J Neurooncol
September 2025
Department of Radiation Oncology, Stanford University, Stanford, CA, USA.
Purpose: We report outcomes of repeat stereotactic radiosurgery (rSRS) to sites of tumor progression following initial SRS. Additionally, we sought to determine if, at the time of recurrence following initial SRS, surgical resection of the tumor followed by SRS (surgery + rSRS) provided benefit compared to rSRS alone.
Methods: We retrospectively reviewed patients treated with rSRS for local recurrence after initial SRS.
PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group.
Clin Transl Oncol
September 2025
Spanish Society of Medical Oncology (SEOM) Thrombosis and Cancer Group, Madrid, Spain.
Purpose: To determine the real-world incidence and predictive factors for venous and arterial thromboembolic events (VTE/AT) in ovarian cancer patients treated with poly-(ADP-ribose) polymerase inhibitors (iPARP).
Methods/patients: A multicenter retrospective study involving 329 ovarian cancer patients who initiated iPARP treatment between January 2015 and December 2022. The primary outcome was the incidence of VTE/AT.
The molecular mechanisms and therapeutic implications of PANoptosis in ischemic diseases.
Apoptosis
September 2025
Key Laboratory of Emergency and Trauma of the Ministry of Education, Department of Interventional Radiology and Vascular Surgery, First Affiliated Hospital of Hainan Medical University, Hainan Medical University, 31 Longhua Road, Longhua District, Haikou City, Hainan Province, China.
The singular forms of programmed cell death (PCD), including pyroptosis, apoptosis, and necroptosis, are inadequate for comprehensively elucidating the complex pathological mechanisms underlying ischemic diseases. PANoptosis is a unique lytic, innate immune, and inflammatory cell death pathway, initiated by innate immune sensors and driven by caspases and RIPKs through PANoptosome complexes. In diseases like cerebral ischemia, retinal ischemia, myocardial ischemia, renal ischemia, and spinal cord ischemia, targeting key regulatory factors of PANoptosis can help mitigate tissue damage.
View Article and Find Full Text PDFAdvancing driving rehabilitation in Korea: the development of a tailored ICF Core Set.
Disabil Rehabil
September 2025
Department of Occupational Therapy, Yonsei University Graduate School, Seoul, South Korea.
Purpose: This study aimed to develop a tailored International Classification of Functioning, Disability and Health (ICF) Core Set for driving rehabilitation in South Korea, addressing the functional needs of individuals with disabilities and the gaps in the current rehabilitation system.
Materials And Methods: An initial item pool was created based on focus group interviews with 13 individuals with disabilities who use assistive driving technologies. This was followed by two Delphi rounds with 12 occupational therapy experts.
Valid measures of cognitive assessment with Aboriginal and Torres Strait Islander peoples are urgently needed: construct and concurrent validity of the Perceive, Recall, Plan and Perform Assessment (PRPP-A).
Disabil Rehabil
September 2025
Occupational Performance Network, Sydney, Australia.
Purpose: Initial studies identified the Perceive, Recall, Plan and Perform Assessment (PRPP-A) as a cognitive assessment with potential for culturally safe use with Aboriginal and Torres Strait Islander peoples with neurocognitive impairments in the Northern Territory of Australia. This study examines construct and concurrent validity of the PRPP-A.
Methods: Data were collected from a medical record review.